The eye is a very important organ for humans, and as eye health becomes more and more important, the size of the ophthalmic medical market has begun to show a steady growth trend
.
According to Frost & Sullivan, the overall size of China's ophthalmic market has reached 210 billion yuan
in 2021.
Among them, the ophthalmic service market accounts for a relatively large proportion, accounting for 71% of the overall size of the ophthalmic market, and ophthalmic devices account for about
17%.
At present, with its steady growth, the ophthalmic treatment market has become the key area
of the strategic layout of many pharmaceutical companies at home and abroad.
Recently, many companies have ushered in good news in
this field.
Recently, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration announced that the class 5.
1 new drug Bemeprost Intraroom Implant declared by Allergan, a subsidiary of AbbVie, has been approved for clinical trial and is suitable for reducing intraocular pressure in patients with open-angle glaucoma (OAG) or hyperocular pressure
(OHT).
Bemeiprost Antechamber Implant is a long-acting glaucoma treatment that effectively reduces intraocular pressure
.
The product is a biodegradable, sustained-release implant that can be implanted in the anterior chamber of the patient's eye with a long-term slow release of bemeiprost
.
On December 15, Xingqi Eye Medicine announced that the company has completed a "randomized, double-blind, placebo-controlled, multi-center 1-year clinical trial of the efficacy and safety of atropine sulfate eye drops in delaying the progression of myopia in children"
.
After data management and statistical analysis, the summary report
of phase III.
clinical trial of atropine sulfate eye drops for 1 year has been obtained.
It is understood that the atropine sulfate eye drops announced this time are ophthalmic preparations with atropine sulfate as the active ingredient, and the indication is to delay the progression of
myopia in children.
The results showed that there was a statistically significant difference in the main efficacy indicators between the atropine sulfate eye drop group and the placebo group, and the atropine sulfate eye drop group was better than the placebo group, with good safety and good patient compliance
.
The industry believes that Xingqi product research and development progress is in a leading position, and is expected to become the first domestic enterprise
approved for the marketing of low-concentration atropine eye drops.
On November 24, Kanghong Pharmaceutical announced that KH631 ophthalmic injection was approved for clinical trials in the United States for the treatment of neovascular (wet) age-related macular degeneration
.
KH631 ophthalmic injection is a class 1 new therapeutic biological product with independent intellectual property rights for the treatment of neovascular (wet) age-related macular degeneration by adeno-associated virus delivery of target genes
.
On November 15, 2022, the above-mentioned new drugs have obtained the notification of clinical trial approval from the China Medical Products Administration (NMPA) and agreed to carry out clinical trials
.
After the approval of clinical trials in the United States, Kanghong Pharmaceutical said that it will carry out follow-up work
in accordance with the relevant regulations and requirements of US drug registration according to the actual situation.
.
.
.
.
.
.
It is worth noting that although under the efforts of many enterprises, the ophthalmic treatment track has entered a stage of rapid development, and the results are constantly emerging, but on the whole, the current progress of basic research related to ophthalmic diseases in China is still relatively slow, and the research and development of drugs is also concentrated on new processes and new dosage forms, and the indications are mainly concentrated in glaucoma and high intraocular pressure; Therefore, the industry believes that in order to meet the vast and continuous market demand for ophthalmic treatment, relevant companies still need to accelerate
the exploration and innovation of new targets in the future.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
